Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

v3.20.1
Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2020
Net Loss Per Share  
Schedule of reconciliation of net loss

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

 

March 31,

 

    

2020

    

2019

Net loss

 

$

(6,373,420)

 

$

(5,819,081)

Net loss - Non-controlling interest

 

 

(81,314)

 

 

(103,605)

Net loss attributable to Heat Biologics, Inc.

 

$

(6,292,106)

 

$

(5,715,476)

 

 

 

 

 

 

 

Weighted-average number of common shares used in net loss per share attributable to common stockholders —basic and diluted

 

 

57,282,075

 

 

33,225,164

Net loss per share attributable to Heat Biologics, Inc —basic and diluted

 

$

(0.11)

 

$

(0.17)

 

Schedule of potentially dilutive securities

 

 

 

 

 

 

 

For the Three Months Ended

 

 

March 31, 

 

    

2020

    

2019

Outstanding stock options

 

5,595,560

 

3,008,754

Restricted stock subject to forfeiture and restricted stock units

 

2,025,215

 

838,679

Outstanding common stock warrants

 

5,779,064

 

9,030,730